On 3/25/25, Avalo Therapeutics Inc (NASDAQ: AVTX) stock enjoyed a major increase of 11.9%, closing at $8.54. Moreover, exceptionally high trading volume at 383% of normal accompanied the advance. The stock has risen 11.1% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Avalo Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Avalo Therapeutics has a slightly negative Appreciation Score of 31 and a very low Power Rating of 2, leading to the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment